Charles River Laboratories International, Inc. (NYSE:CRL) Shares Bought by Twinbeech Capital LP

Twinbeech Capital LP increased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 1,584.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 44,480 shares of the medical research company's stock after purchasing an additional 41,840 shares during the quarter. Twinbeech Capital LP owned 0.09% of Charles River Laboratories International worth $8,211,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Optiver Holding B.V. acquired a new stake in Charles River Laboratories International during the 4th quarter worth approximately $37,000. GeoWealth Management LLC boosted its holdings in Charles River Laboratories International by 311.5% in the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock worth $46,000 after acquiring an additional 190 shares during the period. Pilgrim Partners Asia Pte Ltd purchased a new position in Charles River Laboratories International in the 4th quarter worth approximately $48,000. Tortoise Investment Management LLC boosted its holdings in Charles River Laboratories International by 77.7% in the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock worth $49,000 after acquiring an additional 115 shares during the period. Finally, Huntington National Bank boosted its holdings in Charles River Laboratories International by 120.6% in the 4th quarter. Huntington National Bank now owns 300 shares of the medical research company's stock worth $55,000 after acquiring an additional 164 shares during the period. Institutional investors and hedge funds own 98.91% of the company's stock.

Charles River Laboratories International Price Performance

Shares of CRL opened at $141.36 on Tuesday. The firm has a market capitalization of $6.94 billion, a price-to-earnings ratio of 942.40, a price-to-earnings-growth ratio of 4.54 and a beta of 1.50. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $254.15. The stock's fifty day moving average is $134.84 and its 200-day moving average is $164.49.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. The company had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company's quarterly revenue was down 2.7% compared to the same quarter last year. During the same period last year, the company earned $2.27 earnings per share. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Buying and Selling

In related news, EVP Joseph W. Laplume sold 500 shares of the stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the transaction, the executive vice president now owns 19,513 shares in the company, valued at $2,837,385.33. This trade represents a 2.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO James C. Foster purchased 6,075 shares of the firm's stock in a transaction that occurred on Thursday, February 20th. The stock was bought at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the transaction, the chief executive officer now directly owns 183,639 shares in the company, valued at $30,302,271.39. This trade represents a 3.42% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 5,040 shares of company stock valued at $807,407 over the last three months. Company insiders own 1.30% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on CRL shares. Morgan Stanley decreased their price target on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a report on Wednesday, February 5th. JPMorgan Chase & Co. reduced their target price on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a research note on Thursday, February 20th. Mizuho reduced their target price on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research note on Wednesday, April 9th. Redburn Atlantic upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price objective on the stock in a research note on Monday, March 3rd. Finally, The Goldman Sachs Group cut Charles River Laboratories International from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $190.00 to $170.00 in a research note on Friday, March 21st. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $172.31.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.